IGF-1 LR3: Molecular Characterization and Receptor Pharmacology — A Research Reference

The parent, insulin-like growth factor 1, is a 70-residue protein of approximately 7,650 daltons. Its solution structure was determined by nuclear magnetic resonance and restrained molecular dynamics, establishing a fold in which three disulfide bridges formed among six cysteines hold the chain in a compact arrangement related to that of insulin [2]. That internal architecture — rather than the linear sequence alone — defines the correctly folded molecule; a chain with the right residues in the wrong pairing is a different entity.

LR3 denotes two modifications. The first is a substitution: arginine replaces the glutamate at position 3, the R3 of the name. The second is an extension: a thirteen-residue sequence appended at the amino terminus, the L for long. Together they bring the molecule to 83 residues and approximately 9,110 daltons.

Both sit outside the disulfide-bonded core, and both address the same property. The parent associates tightly in solution with a family of binding proteins, and the analogue work that produced this construct systematically varied N-terminal structure to establish how much of the parent's apparent activity derived from binding-protein association rather than from receptor engagement [1]. The modifications reduce that association; the receptor-engaging surface is left structurally intact.

The Target Receptor

The type 1 insulin-like growth factor receptor, IGF-1R, is a receptor tyrosine kinase and not a G-protein-coupled receptor — a structural class apart from most of this catalogue. It is a disulfide-linked dimer assembled before ligand binding, so activation cannot proceed by the ligand-induced dimerization mechanism common to single-chain receptor kinases.

Cryo-electron microscopy resolved how activation actually occurs: ligand binding drives a large conformational rearrangement of the pre-formed dimer, converting an inverted-V arrangement of the extracellular region into a form that brings the intracellular kinase domains into proximity [3]. That structural picture is the framework in which IGF-1R ligand pharmacology is now interpreted.

Why binding proteins matter to the assay

The IGF binding proteins are the reason this analogue exists. In any medium containing them, a substantial fraction of an IGF-1 preparation is sequestered rather than free to engage the receptor, so apparent activity reflects the sum of receptor affinity and binding-protein affinity. The analogue series established the relative weight of those two contributions directly [1].

For experimental design the consequence is concrete: characterization of this construct against the parent is only interpretable when the binding-protein content of the medium is defined, since that is the variable the modifications were built to address.

Characterization of a recombinant protein differs in kind from the synthetic-peptide case.

Mass spectrometry confirms the intact mass near 9,110 daltons, separating the modified construct from the unmodified parent by a wide margin. It also reports on the disulfides: forming three bridges releases six hydrogens, so the correctly folded protein is six daltons lighter than the fully reduced chain.

Size-exclusion chromatography and SDS-PAGE address a question that does not arise for short peptides — aggregation — by separating monomer from dimer and higher-order species.

Reversed-phase HPLC yields the purity figure, with misfolded disulfide isomers as the compound-specific related substance: identical mass, different retention, invisible to mass measurement alone.

Host cell protein and endotoxin assays belong to recombinant material specifically, quantifying residual protein from the expression organism and bacterial lipopolysaccharide respectively. Neither has an equivalent on a synthetic peptide certificate.

Content is stated for the protein itself where an excipient is present, since a nominal milligram figure may describe total solid rather than protein alone.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Two behaviours separate this from peptide handling. Proteins adsorb to glass and plastic surfaces, and where only a milligram is present the proportion lost to container walls is not negligible — low-binding labware is the standard mitigation. And mechanical stress promotes aggregation: a folded protein unfolds at air-liquid interfaces, so vigorous agitation is avoided in a stronger sense here than the general caution applied to short peptides.

Reconstituted material is held cold and used within the window the receiving facility's protocols specify. Freeze-thaw cycling is avoided more strictly than for peptides, because each cycle concentrates solutes at the ice interface and drives aggregation.

The disulfide architecture adds its own sensitivity: reducing agents cleave the bridges and alkaline conditions promote disulfide exchange, so a fold that took a manufacturing step to establish can be undone at the bench with no visible change to the solution.

IGF-1 LR3 is an investigational compound. It has not been approved by the FDA or any other regulatory authority, and no manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade IGF-1 LR3 is accompanied by an independent certificate of analysis specific to that lot.

IGF-1 LR3 is an 83-residue recombinant protein of approximately 9,110 daltons: insulin-like growth factor 1 carrying an arginine substitution at position 3 and a thirteen-residue N-terminal extension, with the parent's three disulfide bridges intact. It is characterized against IGF-1R, a pre-dimerized receptor tyrosine kinase whose ligand-driven conformational activation has been resolved structurally, and its modifications target binding-protein association rather than receptor engagement. Analytical verification rests on mass confirmation of construct and disulfide state, size-based assessment of aggregation, recombinant-specific cleanliness assays, and stated protein content.